Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study
Articolo
Data di Pubblicazione:
2019
Abstract:
It is paramount to identify predictors of treatment failure with direct antiviral agents in 'field-practice' patients, including people who inject drugs (PWID). Data on the efficacy of glecaprevir/pibrentasvir (GLE/PIB) in a field-practice scenario are scant. The multicenter MISTRAL study enrolled 1,177 patients, including PWID, to assess real-life efficacy and safety of GLE/PIB and to identify the predictive factors for this treatment.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Direct-acting antiviral; HCV genotype; cirrhosis; efficacy; substance abuse
Elenco autori:
Persico, Marcello; Aglitti, Andrea; Milella, Michele; Coppola, Carmine; Messina, Vincenzo; Claar, Ernesto; Gentile, Ivan; Sogari, Fernando; Pierri, Paola; Surace, Lorenzo Antonio; Morisco, Filomena; Tundo, Paolo; Brancaccio, Giuseppina; Serviddio, Gaetano; Gatti, Pietro; Termite, Antonio Patrizio; Di Costanzo, Giovan Giuseppe; Caroleo, Benedetto; Cozzolongo, Raffaele; Coppola, Nicola; Longo, Annamaria; Fontanella, Luca; Federico, Alessandro; Rosato, Valerio; Terrenato, Irene; Masarone, Mario
Link alla scheda completa:
Pubblicato in: